Bohlius, J

Bonnet, F

Boue, F

Chene, G

Clifford, G

Egger, M

Fatkenheuer, G

May, M

Miro, JM

Mocroft, A

Murillo, AMC

Prins, M

Schmidlin, K

Touloumi, G

The risk of Hodgkin lymphoma (HL) is increased in patients infected with HIV-1. We studied incidence and outcomes of HL, and compared CD4-positive T-cell trajectories in HL patients and controls matched for duration of combination antiretroviral therapy (cART). A total of 40 168 adult HIV-1 infected patients (median age 36 years, 70% male, median CD4 cell count 234 cells/μL) from 16 European cohorts were observed during 159 133 person-years; 78 patients developed HL. The incidence was 49.0 (95% CI 39.3 to 61.2) per 100 000 person-years, and similar on cART and not on cART (P = 0.95). The risk of HL declined as the most recent (time-updated) CD4 count increased: the adjusted hazard ratio comparing &gt;350 withThe risk of Hodgkin lymphoma (HL) is increased in patients infected with HIV-1. We studied incidence and outcomes of HL, and compared CD4-positive T-cell trajectories in HL patients and controls matched for duration of combination antiretroviral therapy (cART). A total of 40 168 adult HIV-1 infected patients (median age 36 years, 70% male, median CD4 cell count 234 cells/μL) from 16 European cohorts were observed during 159 133 person-years; 78 patients developed HL. The incidence was 49.0 (95% CI 39.3 to 61.2) per 100 000 person-years, and similar on cART and not on cART (P = 0.95). The risk of HL declined as the most recent (time-updated) CD4 count increased: the adjusted hazard ratio comparing &gt;350 wit

Explore Bristol Research

HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence, outcome and evolution of CD4+ T cell lymphocytes

HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence, outcome and evolution of CD4+ T cell lymphocytes

Abstract

Similar works

Full text

Available Versions

Explore Bristol Research